» Articles » PMID: 32619088

A Nuclear LncRNA Linc00839 As a Myc Target to Promote Breast Cancer Chemoresistance Via PI3K/AKT Signaling Pathway

Overview
Journal Cancer Sci
Specialty Oncology
Date 2020 Jul 4
PMID 32619088
Citations 33
Authors
Affiliations
Soon will be listed here.
Abstract

Chemoresistance has become a leading cause of mortality in breast cancer patients and is one of the major obstacles for improving the clinical outcome. Long noncoding RNAs play important roles in breast cancer tumorigenesis and chemoresistance. However, the involvement and regulation of lncRNAs in breast cancer chemoresistance are not completely understood. Here, we reported that Linc00839 was localized in the nucleus and upregulated in chemoresistant breast cancer cells and tissues, and high level of Linc00839 was associated with a poor prognosis. Knockdown of Linc00839 significantly suppressed proliferation, invasion, and migration, sensitized cells to paclitaxel in vitro and inhibited transplant tumor development in vivo. Mechanistically, we found that Myc could directly bind to the promoter region of Linc00839 and activate its transcription. Furthermore, Linc00839 overexpression increased the expression of Myc and the RNA-binding protein Lin28B and activated the PI3K/AKT signaling pathway. We also discovered that Lin28B positively interacted with Linc00839 and was upregulated in breast cancer tissues. Taken together, for the first time, we showed that Linc00839 was activated by Myc and promoted proliferation and chemoresistance in breast cancer through binding with Lin28B. These findings provide new insight into the regulatory mechanism of Linc00839 and propose a Myc/Linc00839/Lin28B feedback loop that could be used as a novel therapeutic target for breast cancer.

Citing Articles

The role of long non-coding RNA LINC00839 in oral squamous cell carcinoma based on bioinformatics and experimental research.

Kalantary-Charvadeh A, Morovat S, Aslani S, Ziamajidi N, Emami Razavi A, Abbasalipourkabir R Sci Rep. 2024; 14(1):31817.

PMID: 39738469 PMC: 11686358. DOI: 10.1038/s41598-024-82922-6.


Exosomal long non-coding RNA-LINC00839 promotes lung adenocarcinoma progression by activating NF-κB signaling pathway.

Sun Y, Zhen F, Wang H, Liang X, Wang Y, Wang F Ann Med. 2024; 56(1):2430029.

PMID: 39582330 PMC: 11590188. DOI: 10.1080/07853890.2024.2430029.


Targeting c-Met in breast cancer: From mechanisms of chemoresistance to novel therapeutic strategies.

Iweala E, Amuji D, Oluwajembola A, Ugbogu E Curr Res Pharmacol Drug Discov. 2024; 7:100204.

PMID: 39524211 PMC: 11543557. DOI: 10.1016/j.crphar.2024.100204.


Emerging roles of non-coding RNAs in modulating the PI3K/Akt pathway in cancer.

Hashemi M, Khosroshahi E, Asadi S, Tanha M, Ghatei Mohseni F, Abdolmohammad Sagha R Noncoding RNA Res. 2024; 10:1-15.

PMID: 39296640 PMC: 11406677. DOI: 10.1016/j.ncrna.2024.08.002.


Unraveling the role of long non-coding RNAs in therapeutic resistance in acute myeloid leukemia: New prospects & challenges.

Sharma S Noncoding RNA Res. 2024; 9(4):1203-1221.

PMID: 39036603 PMC: 11259994. DOI: 10.1016/j.ncrna.2024.05.009.


References
1.
Meder L, Konig K, Dietlein F, Macheleidt I, Florin A, Ercanoglu M . LIN28B enhanced tumorigenesis in an autochthonous KRAS-driven lung carcinoma mouse model. Oncogene. 2018; 37(20):2746-2756. DOI: 10.1038/s41388-018-0158-7. View

2.
Wang C, Gu Y, Zhang E, Zhang K, Qin N, Dai J . A cancer-testis non-coding RNA LIN28B-AS1 activates driver gene LIN28B by interacting with IGF2BP1 in lung adenocarcinoma. Oncogene. 2018; 38(10):1611-1624. DOI: 10.1038/s41388-018-0548-x. View

3.
Kugel S, Sebastian C, Fitamant J, Ross K, Saha S, Jain E . SIRT6 Suppresses Pancreatic Cancer through Control of Lin28b. Cell. 2016; 165(6):1401-1415. PMC: 4892983. DOI: 10.1016/j.cell.2016.04.033. View

4.
Li Z, Chao T, Chang K, Lin N, Patil V, Shimizu C . The long noncoding RNA THRIL regulates TNFα expression through its interaction with hnRNPL. Proc Natl Acad Sci U S A. 2013; 111(3):1002-7. PMC: 3903238. DOI: 10.1073/pnas.1313768111. View

5.
Guerrero-Zotano A, Mayer I, Arteaga C . PI3K/AKT/mTOR: role in breast cancer progression, drug resistance, and treatment. Cancer Metastasis Rev. 2016; 35(4):515-524. DOI: 10.1007/s10555-016-9637-x. View